News | November 28, 2023
Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Phase 3 data expected in the second half of 2024
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The initiative will focus on advocating for cleaner air
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Subscribe To Our Newsletter & Stay Updated
